Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $3.60
Volume
1.65 M
Value Traded
469.08 K
Short % Float
4.99%
Days to Cover
4.8
+12.66%Week
-1.3%1 Month
-0.44%3 Month
-7.72%6 Month
-89.99%5 Year
-89.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
164.16 M
EPS (TTM)
-1.45
P/E Ratio
-
Ent. Value
111.83 M
Total Shares
72.32 M
Float Shares
61.76 M
Insiders
14.60%
Institutions
58.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ABOS Catalyst Timeline
Dated clinical, regulatory and corporate events for Acumen Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Acumen Pharmaceuticals, Inc.
218Total events
8Upcoming
29Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Development Candidate NominationPreclinical
Two candidates nominated for development in EBD program
◆Poster PresentationPresentation
EBD program data and ALTITUDE-AD patient experience data presented at AAIC 2026
Alzheimer's diseasesource ↗
▲Enrollment CompletesabirnetugTrial
Enrollment completed with 542 participants
early Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Acumen exercises exclusive option to develop Alzheimer's candidates using J-Brain Cargo platform
Alzheimer's Diseasesource ↗
▲Development Candidate NominationACU301Preclinical
Nomination of ACU301 as EBD development candidate
Alzheimer's diseasesource ↗
▲Development Candidate NominationACU401Preclinical
Nomination of ACU401 as EBD development candidate
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Fireside chat at Bank of America Securities 2026 Health Care Conference
▲Partnership / LicenseCorporate
Exercise option to license two compounds from JCR Pharmaceuticals collaboration
Alzheimer's diseasesource ↗
◆Oral PresentationsabirnetugPresentation
Enhanced Brain Delivery of Sabirnetug After Fusion with an Anti-Transferrin Receptor Antibody Fragment in a Mouse Model of Alzheimer’s Disease
Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Management to participate in Stifel 2026 Virtual CNS Forum fireside chat
◆Oral PresentationsabirnetugPresentation
Oral presentation on Enhanced Brain Delivery of sabirnetug at AD/PD 2026
Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster presentation on sabirnetug biomarker treatment responses using NULISAseq at AD/PD 2026
Alzheimer's diseasesource ↗
◆Poster PresentationACU234Presentation
Poster presentation on novel anti-AβO antibody ACU234 at AD/PD 2026
Alzheimer's diseasesource ↗
◆Poster PresentationPresentation
Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity
Alzheimer's diseasesource ↗
▲Preclinical PoCPreclinical
Preclinical data for EBD program including NHP study results
Alzheimer's diseasesource ↗
◆Oral PresentationsabirnetugPresentation
Oral presentation at AD/PD 2026 on EBD program and sabirnetug biomarker data
Alzheimer's diseasesource ↗
▲Enrollment CompletesabirnetugTrial
Enrollment completed for ALTITUDE-AD Phase 2 study
early Alzheimer's diseasesource ↗
●Preclinical PoCPreclinical
Preclinical data packages for EBD therapy expected in early 2026
Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster presentation on Enhanced Brain Delivery (EBD) technology with sabirnetug
Alzheimer's diseasesource ↗
●Poster PresentationsabirnetugPresentation
Poster presentation on Enhanced Brain Delivery technology and ALTITUDE-AD recruitment strategies at CTAD 2025
Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster presentation on recruitment strategies for ALTITUDE-AD trial
Alzheimer's diseasesource ↗
▲First Patient DosedsabirnetugTrial
First participant dosed in open-label extension of ALTITUDE-AD
early Alzheimer's diseasesource ↗
◆Oral PresentationPresentation
Management to participate in fireside chat at Stifel Healthcare Conference
▲First Patient DosedsabirnetugTrial
First patient dosed in open-label extension of ALTITUDE-AD
early Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Four poster presentations at AD/PD 2026 and CTAD 2025
Alzheimer's diseasesource ↗
▲Enrollment MilestonesabirnetugTrial
ALTITUDE-AD enrolled 542 participants
Alzheimer's diseasesource ↗
▲Oral PresentationsabirnetugPresentation
Presentation of pTau217 screening assay cost savings and sabirnetug selectivity data at AAIC 2025
Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Collaboration, option and license agreement with JCR Pharmaceuticals for Enhanced Brain Delivery therapy
Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Collaboration with JCR Pharmaceuticals announced July 2025
Alzheimer's diseasesource ↗
▲Oral PresentationsabirnetugPresentation
Presentation at AAIC 2025 on ALTITUDE-AD screening process and sabirnetug selectivity
early Alzheimer's diseasesource ↗
▲Enrollment CompletesabirnetugTrial
ALTITUDE-AD Phase 2 study fully enrolled with 542 participants
early Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster on early effect of sabirnetug on synaptic biomarkers in AD at AAN 2025
Alzheimer's diseasesource ↗
◆Oral PresentationsabirnetugPresentation
Oral presentation on use of plasma pTau217 assay to screen participants in ALTITUDE-AD at AAN 2025
Alzheimer's diseasesource ↗
◆Oral PresentationsabirnetugPresentation
Encore oral presentation of pTau217 enrichment strategy at AAN 2025
Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster on early effect of sabirnetug on synaptic biomarkers at AAN 2025
Alzheimer's diseasesource ↗
◆Poster PresentationsabirnetugPresentation
Poster on utility of human iPSC-derived neuronal model for evaluating synaptic binding of AβOs at AD/PD 2025
Alzheimer's diseasesource ↗
▲Enrollment CompletesabirnetugTrial
ALTITUDE-AD enrollment completed with 542 participants
early Alzheimer's diseasesource ↗
▲Oral PresentationsabirnetugPresentation
Oral presentation of pTau217 enrichment strategy results at AD/PD 2025
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ABOS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-27 | sabirnetug (ACU193) subcutaneous formulation | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 42%
Micro Cap(rank 277 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| sabirnetug Small moleculeNCT06335173 | Alzheimer Disease | Phase 2 | ACTIVE NOT_RECRUITING | 570 | Oct 1, 2026 | ||||||
| ACU193 Small moleculeCompletedNCT04931459 | Alzheimer Disease | Phase 1 | COMPLETED | 65 | Jun 12, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABOS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Porter DerrellDirector | Option | 13,040 48,540 held | $1.07 | 06/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABOS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.5 % | 56.05 M | 20.99 M |
ABOS Institutional Ownership Trends
ABOS Short Interest
Shares sold short, counted twice a month.
4.99%
Short % of Float
of tradable shares sold short
3.1M
Shares Sold Short
+9.8% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
641.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABOS ranks across every disease it competes in
Competitive Position is a premium feature
See how ABOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABOS News
ABOS▲ +14.6%on this news
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported its third quarter 2026 financial results, highlighting an expected topline result from the ALTITUDE-AD Phase 2 study in November 2026. The company has a cash balance of $78.6 million, which will support its clinical activities into early 2027. Acumen is developing sabirnetug (ACU193) for early Alzheimer's disease treatment.
Read more →ABOSAcumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acumen Pharmaceuticals will present findings from its Phase 2 ALTITUDE-AD trial at the CTAD conference. The presentations will cover baseline characteristics of participants and insights into their experiences and motivations. The trial evaluates sabirnetug (ACU193) for early Alzheimer's disease, with results expected in late 2026.
Read more →ABOS▲ +13.8%on this newsshared move
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Acumen Pharmaceuticals will announce its third quarter financial results on October 26, 2026. The company will hold a conference call at 8:00 a.m. ET to discuss business and financial updates. Acumen is focused on developing therapies for Alzheimer's disease and is currently conducting a Phase 2 clinical trial for its product candidate, sabirnetug.
Read more →ABOSAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Acumen Pharmaceuticals will host a virtual Investor Day on September 16, 2026, at 10:00 a.m. ET. The event aims to provide updates on the company's progress in developing novel therapeutics for Alzheimer's disease, particularly focusing on their lead candidate, sabirnetug. Participants can register in advance to join the live conference call.
Read more →ABOSAcumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals, Inc. will participate in two upcoming investor conferences: the Cantor Global Healthcare Conference on September 9, 2026, and Citi's Biopharma Back to School Conference on September 10, 2026. The company is developing therapies targeting amyloid beta oligomers for Alzheimer's disease and is currently conducting a Phase 2 trial for its lead candidate, sabirnetug.
Read more →ABOSAcumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals has reported its financial results for the second quarter of 2026, highlighting significant advancements in its research. The company anticipates topline results from the Phase 2 ALTITUDE-AD study on sabirnetug (ACU193) for early Alzheimer's disease by late 2026. Additionally, two candidates have been nominated for its Enhanced Brain Delivery program, with an IND filing for the lead candidate in progress.
Read more →ABOSAcumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Acumen Pharmaceuticals will report its second quarter financial results on August 12, 2026. The company is focused on developing therapies targeting amyloid beta oligomers for Alzheimer's disease. A conference call will be held at 8:00 a.m. ET to discuss the financial update. Acumen is currently advancing its Phase 2 clinical trial for its product candidate sabirnetug.
Read more →ABOS▼ -12.3%on this news
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals presented promising data at the AAIC 2026 regarding their Enhanced Brain Delivery (EBD) program. The bispecific antibodies developed showed significantly improved brain penetration compared to traditional anti-AβO antibodies. Additionally, the EBD candidate ACU401 exhibited substantial increases in brain exposure in non-human primate models, supporting further development for Alzheimer's disease treatment.
Read more →ABOSAcumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals will present key studies at the Alzheimer's Association International Conference 2026, focusing on their Enhanced Brain Delivery technology and insights into early Alzheimer's disease. The presentations include an oral session on bispecific antibodies and two poster sessions highlighting patient perspectives and drug delivery advancements. These efforts aim to improve treatment options for Alzheimer's disease.
Read more →ABOS▼ -5.5%on this news
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
JCR Pharmaceuticals has announced that Acumen Pharmaceuticals will proceed with the development of therapeutic candidates for Alzheimer's disease. This decision is supported by the J-Brain Cargo® technology platform, which is designed to enhance drug delivery. The collaboration reflects a significant step forward in addressing Alzheimer's disease.
Read more →ABOSAcumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease
Acumen Pharmaceuticals has nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery (EBD) program for Alzheimer's disease. This program combines innovative blood-brain barrier-penetrating technology with therapeutic antibodies. The candidates are designed to enhance brain penetration and safety, with IND submission anticipated by mid-2027. Preclinical studies show promising results in animal models.
Read more →ABOSAcumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported its financial results for Q1 2026, highlighting a strong cash position of $128.4 million, which is expected to support ongoing clinical activities into early 2027. The company anticipates topline results from its ALTITUDE-AD Phase 2 study on sabirnetug for early Alzheimer's disease by late 2026. Despite a decrease in operational losses, the company reported a net loss of $20.7 million for the quarter.
Read more →ABOSAcumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals will participate in the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The company is developing treatments targeting toxic amyloid beta oligomers for Alzheimer's disease and is advancing its lead candidate, ACU193, in a Phase 2 trial. The event will be accessible via a live webcast.
Read more →ABOSAcumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
Acumen Pharmaceuticals will report its first quarter financial results on May 12, 2026. The company is developing novel therapeutics for Alzheimer's disease and will host a conference call to provide updates. Acumen's investigational product, sabirnetug, is currently in Phase 2 trials following positive Phase 1 results.
Read more →ABOSAcumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Acumen Pharmaceuticals reported its financial results for the year ending December 31, 2025, highlighting significant clinical advancements in its Phase 2 ALTITUDE-AD study for early Alzheimer's disease. The company anticipates topline results from this study in late 2026 and plans to submit an IND filing for its Enhanced Brain Delivery program by mid-2027. Despite a strong cash position of $116.9 million, Acumen faced increased R&D expenses resulting in a net loss of $121.3 million.
Read more →ABOS▼ -8.6%on this news
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Acumen Pharmaceuticals will report its fourth quarter and year-end 2025 financial results on March 26, 2026. The company, focused on developing therapies for Alzheimer's disease, will host a conference call at 8:00 a.m. ET to provide updates. Acumen is advancing its product candidate, sabirnetug, in ongoing clinical trials.
Read more →ABOS▼ -7.5%on this news· ran to -20% by day 3shared move
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Acumen Pharmaceuticals recently presented important findings on Alzheimer's disease treatment at the International Conference on Alzheimer's and Parkinson's Diseases. The research focuses on Enhanced Brain Delivery technology, novel biomarker evaluation, and the development of highly selective antibodies targeting toxic amyloid beta oligomers. A collaborative effort with JCR Pharmaceuticals aims to improve drug penetration across the blood-brain barrier, which could enhance therapeutic effectiveness. These advancements highlight Acumen's commitment to addressing key challenges in Alzheimer's drug development.
Read more →ABOSAcumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Acumen Pharmaceuticals announced a $35.75 million private placement to further develop its Enhanced Brain Delivery (EBD) program targeting amyloid beta oligomers for Alzheimer's disease. Strong preclinical data supporting the program includes positive results from non-human primate studies, indicating significantly elevated brain exposure and low potential for anemia. The funding, led by RA Capital Management, is intended to support the nomination of a lead clinical candidate by mid-2027. This development highlights confidence in Acumen's innovative approach to treating Alzheimer's disease.
Read more →ABOS▲ +7%on this news
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Acumen Pharmaceuticals, Inc. will participate in the Stifel 2026 Virtual CNS Forum on March 18, 2026. The company is focused on developing therapeutics targeting toxic Alzheimer’s disease markers, particularly with its investigational drug ACU193. Acumen recently reported positive outcomes in its Phase 1 trial, supporting its ongoing Phase 2 clinical study. Archived webcasts from the forum will be available for viewing post-event.
Read more →ABOSAcumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Acumen Pharmaceuticals will present new findings on its Alzheimer's treatment, sabirnetug, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases. The presentations will cover enhanced brain delivery methods, biomarker treatment responses, and new antibody developments. The conference is set for March 17-21, 2026, in Copenhagen.
Read more →About Acumen Pharmaceuticals, Inc.
Headquarters1210-1220 WASHINGTON STREET, NEWTON, MA, 02465
Founded1996
BIOPHARMAWATCH ELITE PLUS
Trade the next ABOS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime